Too many IPOs at a time: Should you invest in Carraro India IPO?
Too many IPOs at a time: Should you invest in Carraro India IPO?
Between FY22 and FY24, the company recorded a Compound Annual Growth Rate (CAGR) of around 10 per cent in revenue and 67 per cent in net profit.
Between FY22 and FY24, the company recorded a Compound Annual Growth Rate (CAGR) of around 10 per cent in revenue and 67 per cent in net profit.
Ventive Hospitality IPO: A gateway to luxury growth
Between FY22 and FY24, it achieved a Compound Annual Growth Rate (CAGR) of 44 per cent in revenue and a remarkable 138 per cent in net profit.
Between FY22 and FY24, it achieved a Compound Annual Growth Rate (CAGR) of 44 per cent in revenue and a remarkable 138 per cent in net profit.
Triple-digit CAGR pharma player hits the market: Should you invest?
Between FY22 and FY24, the company recorded a Compound Annual Growth Rate (CAGR) of around 285 per cent in revenue and 472 per cent in net profit.
Between FY22 and FY24, the company recorded a Compound Annual Growth Rate (CAGR) of around 285 per cent in revenue and 472 per cent in net profit.
Can this wastewater treatment provider’s IPO match the success of its peers?
The company's peers, Enviro Infra Engineers Ltd and VA Tech Wabag Ltd, delivered multibagger returns to investors!
The company's peers, Enviro Infra Engineers Ltd and VA Tech Wabag Ltd, delivered multibagger returns to investors!
117 per cent Gains in 2 Days: This IPO Becomes a Multibagger Overnight!
A stellar stock market debut doubles investor wealth in just two days
A stellar stock market debut doubles investor wealth in just two days
IPO Analysis: Will this textile company sew up your portfolio gains?
The company delivered a decent return on equity (RoE) of 11 per cent and a return on capital employed (RoCE) of 12 per cent for FY24.
The company delivered a decent return on equity (RoE) of 11 per cent and a return on capital employed (RoCE) of 12 per cent for FY24.
EPC Powerhouse IPO expects 28 per cent listing gains: Is it time to subscribe?
The IPO is showing a strong premium in the grey market ahead of its launch. Read on to discover the recommended course of action.
The IPO is showing a strong premium in the grey market ahead of its launch. Read on to discover the recommended course of action.
DAM Capital Advisors IPO: A gateway to India's capital market boom
From FY22 to FY24, the company achieved a Compound Annual Growth Rate (CAGR) of around 39 per cent in revenue and around 80 per cent in net profit.
From FY22 to FY24, the company achieved a Compound Annual Growth Rate (CAGR) of around 39 per cent in revenue and around 80 per cent in net profit.
Mamata Machinery IPO: Balanced risk and reward for investors
Over the period from FY22 to FY24, the company achieved a Compound Annual Growth Rate (CAGR) of around 10 per cent in revenue and 29 per cent in net profit.
Over the period from FY22 to FY24, the company achieved a Compound Annual Growth Rate (CAGR) of around 10 per cent in revenue and 29 per cent in net profit.
Want to invest in the future of diamonds? Don’t miss this IPO of a 65 per cent global market leader!
Between CY21 and CY23, the company achieved a CAGR of 32 per cent in revenue and 37 per cent in net profit, with an impressive CY23 RoE of 77 per cent and RoCE of 81 per cent.
Between CY21 and CY23, the company achieved a CAGR of 32 per cent in revenue and 37 per cent in net profit, with an impressive CY23 RoE of 77 per cent and RoCE of 81 per cent.
Market cheers for Rekha Jhunjhunwala-backed IPO: Is it a winning bet?
Between FY22 and FY24, the company recorded a Compound Annual Growth Rate (CAGR) of around 54 per cent in revenue and 26 per cent in net profit.
Between FY22 and FY24, the company recorded a Compound Annual Growth Rate (CAGR) of around 54 per cent in revenue and 26 per cent in net profit.
Can Sai Life Sciences ride the global CRDMO wave? A detailed IPO analysis
Sai Life Sciences Ltd, a prominent player in the CRDMO sector, is set to launch its IPO. Dive into the details of this ambitious offering, its financials, valuation, and whether it’s a wise investment for today’s market.
Sai Life Sciences Ltd, a prominent player in the CRDMO sector, is set to launch its IPO. Dive into the details of this ambitious offering, its financials, valuation, and whether it’s a wise investment for today’s market.